Table 3.
Subgroup analysis of the associations between 90-day all-cause mortality and the SIRI.
| No. of patients | SIRI | P for interaction | |||
|---|---|---|---|---|---|
| <2.0 | 2.0–4.9 | >4.9 | |||
| Age, years | 0.7111 | ||||
| <78.4 | 1,982 | 1.0 | 1.38 (1.05, 1.83) | 1.79 (1.37, 2.34) | |
| ≥78.4 | 1,982 | 1.0 | 1.39 (1.10, 1.75) | 1.77 (1.41, 2.20) | |
| Sex | 0.2708 | ||||
| Male | 2,020 | 1.0 | 1.26 (0.97, 1.63) | 1.84 (1.44, 2.34) | |
| Female | 1,944 | 1.0 | 1.50 (1.17, 1.92) | 1.69 (1.33, 2.15) | |
| Atrial fibrillation | 0.1334 | ||||
| No | 1,841 | 1.0 | 1.60 (1.21, 2.11) | 2.14 (1.64, 2.80) | |
| Yes | 2,123 | 1.0 | 1.24 (0.98, 1.57) | 1.51 (1.21, 1.88) | |
| CAD | 0.0170 | ||||
| No | 2,170 | 1.0 | 1.25 (1.00, 1.56) | 1.45 (1.17, 1.80) | |
| Yes | 1,794 | 1.0 | 1.66 (1.23, 2.23) | 2.41 (1.82, 3.19) | |
| Valvular disease | 0.5037 | ||||
| No | 2,781 | 1.0 | 1.30 (1.04, 1.61) | 1.66 (1.35, 2.04) | |
| Yes | 1,183 | 1.0 | 1.58 (1.16, 2.15) | 2.04 (1.51, 2.75) | |
| Hypertension | 0.8387 | ||||
| No | 1,140 | 1.0 | 1.41 (1.04, 1.92) | 1.68 (1.25, 2.26) | |
| Yes | 2,824 | 1.0 | 1.36 (1.09, 1.69) | 1.78 (1.45, 2.20) | |
| Complicated diabetes | 0.7627 | ||||
| No | 3,456 | 1.0 | 1.39 (1.15, 1.68) | 1.74 (1.45, 2.08) | |
| Yes | 508 | 1.0 | 1.40 (0.83, 2.36) | 2.04 (1.23, 3.37) | |
| Peripheral vascular disease | 0.3251 | ||||
| No | 3,367 | 1.0 | 1.47 (1.21, 1.78) | 1.81 (1.51, 2.19) | |
| Yes | 597 | 1.0 | 1.01 (0.64, 1.60) | 1.56 (1.03, 2.38) | |
| Respiratory failure | 0.6203 | ||||
| No | 2,376 | 1.0 | 1.38 (1.08, 1.77) | 1.81 (1.43, 2.31) | |
| Yes | 1,588 | 1.0 | 1.34 (1.03, 1.73) | 1.55 (1.21, 1.97) | |
| COPD | 0.5458 | ||||
| No | 3,664 | 1.0 | 1.40 (1.16, 1.69) | 1.82 (1.52, 2.17) | |
| Yes | 300 | 1.0 | 1.21 (0.64, 2.27) | 1.29 (0.69, 2.40) | |
| CKD | 0.3040 | ||||
| No | 2,448 | 1.0 | 1.48 (1.18, 1.85) | 1.72 (1.38, 2.14) | |
| Yes | 1,516 | 1.0 | 1.25 (0.93, 1.67) | 1.86 (1.42, 2.44) | |
| MAP, mmHg | 0.5808 | ||||
| <72.1 | 1,979 | 1.0 | 1.32 (1.04, 1.68) | 1.57 (1.25, 1.97) | |
| ≥72.1 | 1,979 | 1.0 | 1.47 (1.12, 1.92) | 2.00 (1.54, 2.60) | |
| Hemoglobin, g/dl | 0.2972 | ||||
| <10.8 | 1,917 | 1.0 | 1.33 (1.05, 1.68) | 1.49 (1.18, 1.88) | |
| ≥10.8 | 2,046 | 1.0 | 1.48 (1.13, 1.94) | 2.16 (1.67, 2.78) | |
| RDW, % | 0.1289 | ||||
| NA | 1,915 | 1.0 | 1.70 (1.26, 2.29) | 2.28 (1.71, 3.02) | |
| NA | 2,046 | 1.0 | 1.23 (0.98, 1.53) | 1.52 (1.22, 1.88) | |
| White blood cell count, 109/L | 0.4807 | ||||
| <10.6 | 1,979 | 1.0 | 1.35 (1.08, 1.69) | 1.73 (1.26, 2.38) | |
| ≥10.6 | 1,985 | 1.0 | 1.24 (0.89, 1.74) | 1.49 (1.08, 2.04) | |
| Platelet count, 10 9 /L | 0.1004 | ||||
| <232.0 | 1,964 | 1.0 | 1.21 (0.96, 1.54) | 1.70 (1.35, 2.13) | |
| ≥232.0 | 1,999 | 1.0 | 1.73 (1.31, 2.29) | 2.05 (1.57, 2.69) | |
| Blood urea nitrogen, mg/dl | 0.4992 | ||||
| <32 | 1,957 | 1.0 | 1.43 (1.08, 1.89) | 1.77 (1.34, 2.32) | |
| ≥32 | 2,003 | 1.0 | 1.29 (1.02, 1.62) | 1.63 (1.31, 2.02) | |
| Serum creatinine, mg/dl | 0.1919 | ||||
| <1.4 | 1,803 | 1.0 | 1.45 (1.10, 1.91) | 1.94 (1.48, 2.53) | |
| ≥1.4 | 2,156 | 1.0 | 1.34 (1.06, 1.69) | 1.63 (1.31, 2.03) | |
| Anion gap, mg/dl | 0.0581 | ||||
| <16 | 1,905 | 1.0 | 1.49 (1.15, 1.92) | 2.02 (1.57, 2.60) | |
| ≥16 | 2,027 | 1.0 | 1.24 (0.97, 1.59) | 1.51 (1.20, 1.91) | |
| SAPSII score | 0.3249 | ||||
| <41 | 1,978 | 1.0 | 1.39 (1.03, 1.88) | 1.93 (1.44, 2.59) | |
| ≥41 | 1,986 | 1.0 | 1.35 (1.08, 1.68) | 1.48 (1.20, 1.83) | |
| SOFA score | 0.2252 | ||||
| <4 | 1,474 | 1.0 | 1.38 (0.98, 1.95) | 2.18 (1.57, 3.03) | |
| ≥4 | 2,490 | 1.0 | 1.39 (1.13, 1.71) | 1.57 (1.29, 1.92) | |
SIRI, systemic inflammation response index; MAP, mean arterial pressure; RDW, red cell volume distribution width; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; SOFA, sequential organ failure assessment; SAPS II, simplified acute physiology score II. HR (95% CI) were derived from Cox proportional hazards regression models. Covariates were adjusted as in model 1 (Table 2).